Xarelto Legal Help Center
Those who have suffered internal bleeding or other serious injury after taking Xarelto to prevent blood clots, may be eligible for substantial compensation. For a free legal consultation, please fill out the form to the right or contact us directly at 1-800-305-6000.
Rivaroxaban (Xarelto) was originally marketed as providing the same or slightly better results than warfarin in preventing strokes and other blood clot-related events, but were easier to use because weekly or monthly blood level tests were not required or available. Unfortunately, by the end of it’s first year on the market, Xarelto was found to have caused 2,081 serious adverse events including at least 151 deaths. It was ultimately found that Xarelto, although originally thought to be superior to older classes of anticoagulant drugs, had a substantially higher number of adverse events than other anticoagulant drugs.
The primary adverse event associated with Xarelto is hemorrhage or excessive bleeding. Excessive bleeding is a known risk of all anticoagulant drugs, but what many doctors and patients did not realize about Xarelto was that the risk of these events may actually be higher than similar drugs and because, unlike other anticoagulant drugs, there is no antidote to Xarelto. Hemorrhage due to Xarelto cannot be stopped and is much more likely to lead to patient death than bleeding events occurring in those who take drugs for which there is an antidote.
Adverse bleeding events associated with Xarelto include:
- Excessive Bleeding
- Red or Black Stools
- Frequent Nosebleeds
- Pink or Brown Urine
- Unexplained Bruises or Bruises that Increase in Size
- Coughing up Blood or Blood Clots
- Vomiting Blood or vomit that resembles coffee grounds
- Death
- Bleeding from the Gums
- Excessive Menstruation
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is dangerous and defective.
- The manufacturers of Xarelto marketed the drug as a superior to other anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than in users of other anticoagulant drugs.
- Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
- The makers of the drug continue to market Xarelto as a safe anticoagulant option.
- Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.
- Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting